Coral Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 476417, "name": "Coral Labs.", "stock_name": "Coral Labs.", "full_name": "Coral Laboratories Ltd", "name_url": "stocks-analysis/coral-labs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "503.75", "chg": 1.3, "chgp": "0.26%", "dir": 1, "prev_price": "502.45", "mcapval": "180.00 Cr", "mcap": "Micro Cap", "scripcode": 524506, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE683E01017", "curr_date": "Jun 17, 03:30 PM", "curr_time": "19:46 PM", "last_traded_at": "Jun 17, 03:30 PM IST", "bse_nse_vol": "1.24 k", "exc_status": "Active", "traded_date": "Jun 17, 2026", "traded_date_str": "2026 06 17", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/coral-labs-476417-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Coral Laboratories Gains 5.09%: Profit Surge Amid Mixed Sales Drives Weekly Move", "link": "https://www.marketsmojo.com/news/stocks-in-action/coral-laboratories-gains-509-profit-surge-amid-mixed-sales-drives-weekly-move-4052603", "imagepath": "", "date": "2026-06-14 09:01:32", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Quarterly results reveal profit surge despite sales decline; stock jumps 5.72%</p>\n <p><strong>2 June:</strong> Stock continues upward trend, gaining 1.24% amid mixed market</p>\n <p><strong>3 June:</strong> Flat financial trend reported; stock edges up 0.75%</p>\n <p><strong>4 June:</strong> Marginal gains of 0.62% as market sentiment remains cautious</p>\n <p><strong>5 June:</strong> Profit-taking leads to 3.14% decline; week closes at Rs.497.15</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</d..." }, { "title": "Coral Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-is-rated-sell-4048954", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CoralLaboratori_mojoScore_4048954.png", "date": "2026-06-12 10:10:05", "description": "Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance." }, { "title": "Coral Laboratories Ltd Reports Flat Quarterly Financial Trend Amid Mixed Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/coral-laboratories-ltd-reports-flat-quarterly-financial-trend-amid-mixed-performance-4032649", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CoralLaboratori_fintrenddot_4032649.png", "date": "2026-06-03 08:00:12", "description": "Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a pause in its previously positive growth trajectory. While key profitability metrics have improved notably, revenue growth has contracted, and return on capital employed has hit a new low, raising questions about the sustainability of recent gains." }, { "title": "Are Coral Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-coral-laboratories-ltd-latest-results-good-or-bad-4032387", "imagepath": "", "date": "2026-06-02 19:29:45", "description": "Coral Laboratories Ltd's latest financial results for Q4 FY26 present a mixed picture, highlighting both operational challenges and improvements in profitability metrics. The company reported a net profit of ₹5.22 crores, reflecting a significant year-on-year growth of 84.45%, contrasting with a decline in net sales, which decreased by 5.87% to ₹26.48 crores compared to the same quarter last year. This decline raises concerns about sustainable demand in a competitive pharmaceutical landscape.\n\nDespite the revenue challenges, Coral Laboratories achieved a notable operating profit margin of 23.41%, which is a substantial improvement from 9.53% in the previous year, indicating effective cost management and operational efficiency. This margin expansion, alongside the increase in net profit, suggests that the company is capable of converting sales into profits more effectively, even amidst declining revenue.\n\nOn..." }, { "title": "Coral Laboratories Q4 FY26: Profit Surge Masks Revenue Decline Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/coral-laboratories-q4-fy26-profit-surge-masks-revenue-decline-concerns-4028192", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CoralLaboratori_quaterlyResult_4028192.png", "date": "2026-06-01 14:07:44", "description": "Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer with a market capitalisation of ₹174.00 crores, reported a mixed performance for Q4 FY26 ended March 2026. The company posted a net profit of ₹5.22 crores, representing a robust sequential growth of 87.77% from Q3 FY26's ₹2.78 crores, though the year-on-year comparison showed an 84.45% surge from Q4 FY25's ₹2.83 crores. However, this profit expansion came against a backdrop of declining revenues, with net sales falling 5.87% year-on-year to ₹26.48 crores from ₹28.13 crores in the corresponding quarter last year." }, { "title": "Coral Laboratories Ltd Reports Positive Quarterly Turnaround Amid Mixed Sales Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/coral-laboratories-ltd-reports-positive-quarterly-turnaround-amid-mixed-sales-performance-4026564", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CoralLaboratori_fintrenddot_4026564.png", "date": "2026-06-01 12:00:33", "description": "Coral Laboratories Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, shifting from a previously negative trend to positive growth in key profitability metrics despite a decline in net sales. This shift has prompted an upgrade in the company’s mojo grade from Strong Sell to Sell, reflecting cautious optimism amid ongoing challenges in revenue generation." }, { "title": "Coral Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-is-rated-sell-4016291", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CoralLaboratori_mojoScore_4016291.png", "date": "2026-05-27 10:11:37", "description": "Coral Laboratories Ltd is currently rated 'Sell' by MarketsMOJO, a rating that was last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 May 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "When is the next results date for Coral Laboratories Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-coral-laboratories-ltd-4003845", "imagepath": "", "date": "2026-05-21 23:18:30", "description": "The next results date for Coral Laboratories Ltd is scheduled for 30 May 2026...." }, { "title": "Coral Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-is-rated-sell-3993831", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CoralLaboratori_mojoScore_3993831.png", "date": "2026-05-16 10:10:39", "description": "Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." } ], "total": 173, "sid": "476417", "stock_news_url": "https://www.marketsmojo.com/news/coral-laboratories-476417" }, "announcements": [ { "caption": "Corporate Action-Board approves Dividend", "datetime": "30-May-2026", "details": "Final dividend of ? 2 per share", "source": "BSE" }, { "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance", "datetime": "30-May-2026", "details": "Annua Secretarial Compliance Report for the financial year ended March 31 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Dividend Updates", "datetime": "30-May-2026", "details": "The Board has approved ? 2 per share dividend.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Coral Laboratories Ltd has declared <strong>15%</strong> dividend, ex-date: 19 Sep 25", "dt": "2025-09-19", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Quarterly results reveal profit surge despite sales decline; stock jumps 5.72%

2 June: Stock continues upward trend, gaining 1.24% amid mixed market

3 June: Flat financial trend reported; stock edges up 0.75%

4 June: Marginal gains of 0.62% as market sentiment remains cautious

5 June: Profit-taking leads to 3.14% decline; week closes at Rs.497.15

Week OpenRead full news article

Coral Laboratories Ltd is Rated Sell

2026-06-12 10:10:05

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Read full news article

Coral Laboratories Ltd Reports Flat Quarterly Financial Trend Amid Mixed Performance

2026-06-03 08:00:12

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a pause in its previously positive growth trajectory. While key profitability metrics have improved notably, revenue growth has contracted, and return on capital employed has hit a new low, raising questions about the sustainability of recent gains.

Read full news article

Are Coral Laboratories Ltd latest results good or bad?

2026-06-02 19:29:45

Coral Laboratories Ltd's latest financial results for Q4 FY26 present a mixed picture, highlighting both operational challenges and improvements in profitability metrics. The company reported a net profit of ₹5.22 crores, reflecting a significant year-on-year growth of 84.45%, contrasting with a decline in net sales, which decreased by 5.87% to ₹26.48 crores compared to the same quarter last year. This decline raises concerns about sustainable demand in a competitive pharmaceutical landscape. Despite the revenue challenges, Coral Laboratories achieved a notable operating profit margin of 23.41%, which is a substantial improvement from 9.53% in the previous year, indicating effective cost management and operational efficiency. This margin expansion, alongside the increase in net profit, suggests that the company is capable of converting sales into profits more effectively, even amidst declining revenue. On...

Read full news article

Coral Laboratories Q4 FY26: Profit Surge Masks Revenue Decline Concerns

2026-06-01 14:07:44

Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer with a market capitalisation of ₹174.00 crores, reported a mixed performance for Q4 FY26 ended March 2026. The company posted a net profit of ₹5.22 crores, representing a robust sequential growth of 87.77% from Q3 FY26's ₹2.78 crores, though the year-on-year comparison showed an 84.45% surge from Q4 FY25's ₹2.83 crores. However, this profit expansion came against a backdrop of declining revenues, with net sales falling 5.87% year-on-year to ₹26.48 crores from ₹28.13 crores in the corresponding quarter last year.

Read full news article

Coral Laboratories Ltd Reports Positive Quarterly Turnaround Amid Mixed Sales Performance

2026-06-01 12:00:33

Coral Laboratories Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, shifting from a previously negative trend to positive growth in key profitability metrics despite a decline in net sales. This shift has prompted an upgrade in the company’s mojo grade from Strong Sell to Sell, reflecting cautious optimism amid ongoing challenges in revenue generation.

Read full news article

Coral Laboratories Ltd is Rated Sell

2026-05-27 10:11:37

Coral Laboratories Ltd is currently rated 'Sell' by MarketsMOJO, a rating that was last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

When is the next results date for Coral Laboratories Ltd?

2026-05-21 23:18:30

The next results date for Coral Laboratories Ltd is scheduled for 30 May 2026....

Read full news article

Coral Laboratories Ltd is Rated Sell

2026-05-16 10:10:39

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article